Price T Rowe Associates Inc Zentalis Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,036,911 shares of ZNTL stock, worth $3.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,036,911

Previous 923,901 12.23%

Holding current value

$3.11 Million

Previous $3.78 Million 0.98%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.9 - $4.57 $327,729 - $516,455	113,010 Added 12.23%	1,036,911 $3.82 Million
Q2 2024 Aug 14, 2024	SELL	$4.09 - $16.13 $10.5 Million - $41.4 Million	-2,565,808 Reduced 73.52%	923,901 $3.78 Million
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $6.34 Million - $9.66 Million	585,644 Added 20.17%	3,489,709 $55 Million
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $1.85 Million - $3.79 Million	188,466 Added 6.94%	2,904,065 $44 Million
Q3 2023 Nov 14, 2023	BUY	$19.63 - $28.29 $613,378 - $883,977	31,247 Added 1.16%	2,715,599 $54.5 Million
Q2 2023 Aug 14, 2023	BUY	$17.41 - $30.05 $8.43 Million - $14.5 Million	484,183 Added 22.01%	2,684,352 $75.7 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $378,789 - $585,316	23,469 Added 1.08%	2,200,169 $37.8 Million
Q4 2022 Feb 14, 2023	SELL	$18.07 - $25.6 $741,592 - $1.05 Million	-41,040 Reduced 1.85%	2,176,700 $43.8 Million
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $42.1 Million - $66 Million	-2,080,811 Reduced 48.41%	2,217,740 $48 Million
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $1.8 Million - $5.24 Million	100,371 Added 2.39%	4,298,551 $121 Million
Q1 2022 May 16, 2022	SELL	$41.58 - $80.89 $7.68 Million - $14.9 Million	-184,701 Reduced 4.21%	4,198,180 $194 Million
Q4 2021 Feb 14, 2022	BUY	$66.92 - $84.79 $43.7 Million - $55.3 Million	652,456 Added 17.49%	4,382,881 $368 Million
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $22.1 Million - $34.6 Million	470,857 Added 14.45%	3,730,425 $249 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $81.4 Million - $135 Million	2,175,322 Added 200.63%	3,259,568 $173 Million
Q1 2021 May 17, 2021	SELL	$35.69 - $52.72 $349,048 - $515,601	-9,780 Reduced 0.89%	1,084,246 $47 Million
Q4 2020 Feb 16, 2021	BUY	$31.71 - $57.97 $34.7 Million - $63.4 Million	1,094,026 New	1,094,026 $56.8 Million

Others Institutions Holding ZNTL

# of Institutions

142

Shares Held

67.9M

Call Options Held

48.5K

Put Options Held

89.6K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Zentalis Pharmaceuticals, Inc. Transaction History